TGNA:FRA
Transgene SA
0,67 €
arrow_downward
-0,15%(-0,00100) 1 d.
15. 10., 8:03:18 GMT+2 · EUR
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre TGNA…
Otvoriť
0,67 €
Vysoká
0,67 €
Nízka
0,67 €
Trh. kap.
191,08 mil.
Priem. obj.
0,00
Objem
0,00
Max. za 52 týž.
1,48 €
Min. za 52 týž.
0,60 €
Výnosy na akciu
-0,17 €
Počet zamestnancov
152
Otvoriť
0,67 €
Vysoká
0,67 €
Nízka
0,67 €
Trh. kap.
191,08 mil.
Priem. obj.
0,00
Objem
0,00
Max. za 52 týž.
1,48 €
Min. za 52 týž.
0,60 €
Výnosy na akciu
-0,17 €
Počet zamestnancov
152
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
Stock Titan
·
pred 20 minútami
An energy-efficiency platform's co-founder becomes a director; its CEO joins TROOPS as COO.
Yahoo Finance
·
pred 35 minútami
Nasdaq Completes Acquisition of LeveL Markets, Advancing its Always-On Vision
TradingView
·
pred 18 minútami
Nasdaq, S&P 500 under pressure as tech sell-off deepens; Core PPI comes in hot
CNN
·
pred 3 hodinami
Global tech sell-off deepens as enthusiasm for AI stocks wobbles
Profil
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Informácie o subjekte Transgene SA